Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG141 (Nericovir) plus nucleos(t)ide analogs extension study in chronic hepatitis B
CTR20261381Phase 3Active
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of narecovir in Chronic Hepatitis B (CHB), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20261381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261381.